Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company developing transformative mental health treatments, announced that Chief Medical Officer Amir Inamdar will participate in a panel discussion at the 2025 Milken Institute Future of Health Summit scheduled for November 4-6, 2025, in Washington, D.C. The company's participation in this prestigious healthcare forum comes as Cybin advances two significant psychedelic-based therapeutic programs that could reshape mental healthcare delivery.
The company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, recognizing its potential to address significant unmet medical needs. Simultaneously, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder. Both compounds represent novel approaches to treating conditions that affect millions worldwide.
Cybin's research pipeline includes additional investigational compounds focused on 5-HT receptors, positioning the company at the forefront of neuropsychiatry innovation. The company's operational presence spans Canada, the United States, the United Kingdom, and Ireland, reflecting the global nature of mental health challenges and the international interest in psychedelic-based therapeutics. Investors and stakeholders can access the latest company updates through the corporate newsroom at https://ibn.fm/CYBN.
The Milken Institute Future of Health Summit brings together healthcare leaders, policymakers, researchers, and industry executives to address critical challenges in global health systems. Inamdar's participation provides an opportunity to discuss the evolving regulatory landscape, clinical evidence, and implementation considerations for psychedelic-assisted therapies. As mental health disorders continue to represent a substantial global burden, with depression alone affecting over 280 million people worldwide according to World Health Organization data, novel treatment approaches like those being developed by Cybin could significantly impact healthcare systems and patient outcomes.
The company's focus on developing next-generation neuropsychiatry treatments addresses the limitations of current standard care, including variable efficacy, side effects, and treatment-resistant cases. Cybin's approach to creating proprietary molecules with potentially improved pharmacokinetic profiles represents an important advancement in the field. The full press release detailing the Milken Institute participation is available at https://ibn.fm/8AL6L. As psychedelic medicine continues to gain scientific credibility and regulatory consideration, companies like Cybin are positioned to potentially transform mental healthcare delivery through evidence-based, novel therapeutic options.
